Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Marcus Rashford had a Barcelona debut to forget after he was hooked just over half an hour after coming on - a bow that ...

Facing a $70 billion market loss, Novo Nordisk appointed Maziar Mike Doustdar as its new CEO to navigate intensifying ...

The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

For compounded tirzepatide, Burch’s pharmacy charges between $200 and $400 a month, based on the dose. Without insurance, Mounjaro costs $1,069 per month, and Zepbound is $1,060, according to Lilly.

Novo Nordisk's market value fell by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...